A post-menopausal woman arrives at the ER with chest pain, shortness of breath, and an ECG that refuses to tell a clean story. Is this a heart attack — blocked artery, minutes matter, get the catheter ready? Or is it takotsubo syndrome, “broken heart syndrome,” where emotional or physical stress has temporarily stunned the heart without any arterial obstruction at all?
A new blood-based score called BioTAK, published as an advance article in the European Heart Journal in 2026, is designed to answer that question before anyone threads a catheter into the heart. German Scientists have similarly been pushing boundaries in biological research, recently reviving frozen brain tissue after a week-long deep freeze.
What Five Inputs Tell You About Two Very Different Emergencies
Each biomarker captures a distinct piece of the biological puzzle separating a blocked artery from a stress-overwhelmed heart.
The score draws on four blood biomarkers plus sex:
- NT-proBNP — a heart-strain marker that runs higher in broken heart syndrome patients, whose hearts are under severe stress without a blocked artery causing it.
- PAM — an enzyme tied to stress-hormone surges; elevated in takotsubo because the condition is driven by neurological disruption, not plaque.
- sLOX-1 — a plaque-instability marker; lower in takotsubo patients because their arteries are typically clear.
- LDL cholesterol — heart attack patients tend to carry more adverse cardiovascular risk in their lipid profile.
- Sex — included explicitly because takotsubo overwhelmingly targets post-menopausal women.
Together, these inputs encode two completely different biological stories: a plaque rupture causing a blockage versus a stress-hormone cascade temporarily knocking out heart muscle.
The numbers are striking. Across 3,615 patients drawn from Swiss hospital registries spanning 2011 to 2023, BioTAK achieved an AUC — a measure of diagnostic accuracy where 1.0 is perfect — of 0.97 in development and 0.93 in validation. Nearly 90% of patients were classifiable before invasive angiography, and patients flagged “very unlikely” for takotsubo were correct 99.9% of the time, according to the European Heart Journal study. Researchers described the score as identifying takotsubo before catheterization with “a high degree of accuracy,” according to MedicalXpress.
Promising, With Real Caveats Still Attached
The score’s objectivity is its strength — but two of its biomarkers aren’t yet standard hospital lab tests.
Existing tools like the InterTAK Diagnostic Score already distinguish these conditions, relying on clinical variables such as emotional triggers, psychiatric history, and ECG patterns. Those inputs are harder to standardize at 2 a.m. in a busy ER. BioTAK grounds the call in objective blood markers instead — though sLOX-1 and PAM aren’t routine hospital lab tests yet, and current assays take three to five hours.
Post-menopausal women bear the sharpest diagnostic burden here. Takotsubo accounts for an estimated one to four percent of suspected heart attack presentations, and many of those patients undergo invasive procedures only to find clear arteries. The tool could mean, as StudyFinds framed it, that “a stressed heart doesn’t always” mean a trip to the catheterization lab.
Both study cohorts came from Swiss registries affiliated with the Universities of Zurich and Greifswald. International validation across more diverse populations remains the essential next step before the score can travel beyond its Swiss origins.
BioTAK demonstrates diagnostic accuracy — not whether using it in real ERs actually improves patient outcomes. That requires prospective trials. It is not a clinical standard, not a replacement for physician judgment, and not a home test. Chest pain is always an emergency. Call 911.
